HRP20121010T1 - Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin - Google Patents
Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin Download PDFInfo
- Publication number
- HRP20121010T1 HRP20121010T1 HRP20121010TT HRP20121010T HRP20121010T1 HR P20121010 T1 HRP20121010 T1 HR P20121010T1 HR P20121010T T HRP20121010T T HR P20121010TT HR P20121010 T HRP20121010 T HR P20121010T HR P20121010 T1 HRP20121010 T1 HR P20121010T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- salt
- formula
- dimethylpiperazine
- image
- Prior art date
Links
- FBCSWIXKXHSYBN-AZUAARDMSA-N 1-[(1r,3s)-6-chloro-3-phenyl-2,3-dihydro-1h-inden-1-yl]-3,3-dimethylpiperazine Chemical compound C1CNC(C)(C)CN1[C@H]1C2=CC(Cl)=CC=C2[C@H](C=2C=CC=CC=2)C1 FBCSWIXKXHSYBN-AZUAARDMSA-N 0.000 title claims 2
- 150000001875 compounds Chemical class 0.000 claims 31
- 238000000034 method Methods 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 208000028017 Psychotic disease Diseases 0.000 claims 5
- 238000006243 chemical reaction Methods 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- PIPWSBOFSUJCCO-UHFFFAOYSA-N 2,2-dimethylpiperazine Chemical compound CC1(C)CNCCN1 PIPWSBOFSUJCCO-UHFFFAOYSA-N 0.000 claims 3
- 239000012971 dimethylpiperazine Substances 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- -1 1-protected 2,2-dimethylpiperazine Chemical class 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 208000021465 Brief psychotic disease Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 206010054089 Depressive symptom Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- 206010026749 Mania Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 208000020186 Schizophreniform disease Diseases 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 150000001335 aliphatic alkanes Chemical group 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- 230000000701 neuroleptic effect Effects 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 208000022610 schizoaffective disease Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C17/00—Preparation of halogenated hydrocarbons
- C07C17/093—Preparation of halogenated hydrocarbons by replacement by halogens
- C07C17/16—Preparation of halogenated hydrocarbons by replacement by halogens of hydroxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C25/00—Compounds containing at least one halogen atom bound to a six-membered aromatic ring
- C07C25/18—Polycyclic aromatic halogenated hydrocarbons
- C07C25/22—Polycyclic aromatic halogenated hydrocarbons with condensed rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/132—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group
- C07C29/136—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH
- C07C29/143—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by reduction of an oxygen containing functional group of >C=O containing groups, e.g. —COOH of ketones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C35/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C35/22—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system
- C07C35/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings
- C07C35/32—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a ring other than a six-membered aromatic ring polycyclic, at least one hydroxy group bound to a condensed ring system with hydroxy on a condensed ring system having two rings the condensed ring system being a (4.3.0) system, e.g. indenols
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/003—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions
- C12P41/004—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by ester formation, lactone formation or the inverse reactions by esterification of alcohol- or thiol groups in the enantiomers or the inverse reaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
- C12P7/22—Preparation of oxygen-containing organic compounds containing a hydroxy group aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (21)
1. Farmaceutska smjesa koja sadrži spoj formule (Spoj I, trans-1-((1R,3S)-6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin)
[image]
ili njegovu sol zajedno s barem jednim farmaceutski prihvatljivim nosačem, punilom ili razrjeđivačem.
2. Farmaceutska smjesa prema zahtjevu 1 gdje su Spoj I ili sol u biti čisti.
3. Farmaceutska smjesa prema zahtjevu 1 ili 2 gdje je enantiomerni višak Spoja I barem 90%, barem 96%, ili barem 98%.
4. Uporaba spoja formule (Spoj I, trans-1-((1R,3S)-6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin)
[image]
ili njegove soli u pripremi lijeka za liječenje bolesti izabrane iz grupe koja obuhvaća bolest koja uključuje psihotične simptome, shizofreniju, anksiozne poremećaje, afektivne poremećaje, afektivne poremećaje koji uključuju depresiju, poremećaje spavanja, migrenu, neuroleptički-inducirani parkinsonizam, i poremećaje ovisnosti npr. ovisnost o kokainu, nikotinu ili alkoholu.
5. Uporaba prema zahtjevu 4 u pripremi lijeka za liječenje shizofrenije ili drugih psihotičnih poremećaja.
6. Uporaba prema zahtjevu 5 u pripremi lijeka za liječenje jednog ili više od: pozitivnih simptoma, negativnih simptoma i depresivnih simptoma shizofrenije.
7. Uporaba spoja formule (Spoj I, trans-1-((1R,3S)-6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin)
[image]
ili njegove soli u pripremi lijeka za liječenje bolesti izabrane iz grupe koja obuhvaća shizofreniju, shizofrenoformni poremećaj, shizoafektivni poremećaj, deluzijski poremećaj, kratki psihotični poremećaj, podijeljeni psihotični poremećaj te maniju i bipolarni poremećaj.
8. Uporaba prema bilo kojem od zahtjeva 4-7, gdje su Spoj I ili njegova sol u obliku farmaceutske smjese kako je definirano u zahtjevu 3.
9. Spoj trans-1-(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin ili njegova sol za uporabu u medicini.
10. Farmaceutska smjesa koja sadrži spoj ili sol prema zahtjevu 9 zajedno s barem jednim farmaceutski prihvatljivim nosačem, punilom ili razrjeđivačem.
11. Postupak proizvodnje spoja formule I (Spoj I) ili njegove soli, taj postupak obuhvaća pretvorbu spoja formule Va (Spoj Va) u cis-konfiguraciji u spoj formule I, pri čemu su I i Va:
[image]
12. Postupak prema zahtjevu 11, obuhvaća pretvorbu alkoholne skupine u cis-alkoholu formule Va u odgovarajuću odlazeću skupinu LG, čime se dobiva spoj formule VI.
[image]
13. Postupak prema zahtjevu 12, gdje je LG halogen, npr. Cl ili Br, poželjno Cl, ili sulfonat.
14. Postupak prema bilo kojem od zahtjeva 11-13, gdje se Spoj VI taloži iz odgovarajućeg otapala.
15. Postupak prema zahtjevu 14, gdje je LG halogen, poželjno Cl, i otapalo je alkan, npr. heptan.
16. Postupak prema bilo kojem od zahtjeva 11-15, gdje Spoj VI reagira s 2,2-dimetilpiperazinom da se dobije Spoj I.
17. Postupak prema zahtjevu 16, gdje se Spoj I taloži kao odgovarajuća sol, npr. sol organske kiseline, kao što je organska dikiselina.
18. Postupak prema zahtjevu 17, gdje je nastala sol fumarat ili maleat Spoja I.
19. Postupak prema bilo kojem od zahtjeva 11-15, koji obuhvaća
- reakciju Spoja VI s 1-zaštićenim 2,2-dimetilpiperazinom (VII), gdje je PG zaštitna skupina, npr. izabrana iz grupe koja obuhvaća fenilmetoksikarbonil, tert-butiloksikarbonil, etoksikarbonil, i benzil, čime se dobiva spoj formule VIII; i
- uklanjanje zaštite Spoja VIII da se dobije Spoj I, gdje su Spoj VII i VIII:
[image]
20. Postupak pripreme Spoja I ili njegove soli koji obuhvaća reakciju spoja formule VIa (tj. Spoja VI gdje LG jest C1) s 2,2-dimetilpiperazinom.
21. Postupak pripreme Spoja I ili njegove soli koji obuhvaća reakciju spoja formule VIa
[image]
s 2,2-dimetilpiperazinom u prisutnosti baze.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49605803P | 2003-08-18 | 2003-08-18 | |
| DKPA200301180 | 2003-08-18 | ||
| DKPA200301305 | 2003-09-11 | ||
| US52024603P | 2003-11-14 | 2003-11-14 | |
| PCT/DK2004/000546 WO2005016901A1 (en) | 2003-08-18 | 2004-08-18 | Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20121010T1 true HRP20121010T1 (hr) | 2013-01-31 |
Family
ID=34199055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120389TT HRP20120389T1 (hr) | 2003-08-18 | 2012-05-09 | Soli sukcinata i malonata trans-4-(ir,3s)-6-klor-3-fenilindan-1-il)-1,2,2-trimetilpiperazina i uporaba kao lijek |
| HRP20121010TT HRP20121010T1 (hr) | 2003-08-18 | 2012-12-10 | Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120389TT HRP20120389T1 (hr) | 2003-08-18 | 2012-05-09 | Soli sukcinata i malonata trans-4-(ir,3s)-6-klor-3-fenilindan-1-il)-1,2,2-trimetilpiperazina i uporaba kao lijek |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US7772240B2 (hr) |
| EP (2) | EP1658276B1 (hr) |
| JP (3) | JP5043429B2 (hr) |
| AU (3) | AU2004265021B2 (hr) |
| BR (2) | BRPI0413555A (hr) |
| CA (2) | CA2536073A1 (hr) |
| CY (1) | CY1113039T1 (hr) |
| HR (2) | HRP20120389T1 (hr) |
| IL (2) | IL173589A0 (hr) |
| IS (1) | IS2848B (hr) |
| MX (2) | MXPA06001838A (hr) |
| NO (2) | NO20061153L (hr) |
| NZ (2) | NZ544715A (hr) |
| PL (1) | PL1658277T3 (hr) |
| WO (2) | WO2005016901A1 (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010037398A1 (en) * | 2008-10-03 | 2010-04-08 | H. Lundbeck A/S | Oral formulation |
| EA014685B1 (ru) | 2003-04-25 | 2010-12-30 | Джилид Сайэнс, Инк. | Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе |
| BRPI0413555A (pt) * | 2003-08-18 | 2006-10-17 | Lundbeck & Co As H | composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto |
| ATE505196T1 (de) | 2004-07-27 | 2011-04-15 | Gilead Sciences Inc | Nukleosid phosphonat konjugate als anti hiv mittel |
| JP2008530039A (ja) * | 2005-02-16 | 2008-08-07 | ハー・ルンドベック・アクチエゼルスカベット | トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩 |
| TWI453198B (zh) * | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
| TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
| AU2007254309B2 (en) * | 2006-05-16 | 2012-05-03 | Gilead Sciences, Inc. | Method and compositions for treating hematological malignancies |
| TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
| AU2007307029A1 (en) | 2006-10-06 | 2008-04-17 | Transform Pharmaceuticals, Inc. | Novel crystal of (S)-(+)-2-(2-chlorophenyl)-2-hydroxy-ethyl carbamate |
| CA2673435C (en) * | 2006-12-21 | 2012-10-09 | Pfizer Products Inc. | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1h-pyrazol-3-yl) phenoxy)methyl)quinoline |
| NZ589571A (en) * | 2008-05-07 | 2012-07-27 | Lundbeck & Co As H | Method for treating cognitive deficits using trans-4-((1r,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine |
| US20100093667A1 (en) | 2008-07-08 | 2010-04-15 | Gilead Sciences, Inc. | Salts of hiv inhibitor compounds |
| TW201102370A (en) * | 2009-07-07 | 2011-01-16 | Lundbeck & Co As H | Manufacture of 4-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine and 1-((1R,3S)-6-chloro-3-phenyl-indan-1-yl)-3,3-dimethyl piperazine |
| EP2399904A1 (en) * | 2010-05-26 | 2011-12-28 | Nabriva Therapeutics AG | Process for the preparation of pleuromutilins |
| EP2639216B1 (en) * | 2010-11-09 | 2018-07-11 | Kaneka Corporation | Halogenated indenones and method for producing optically active indanones or optically active indanols by using same |
| CN103429577A (zh) | 2011-01-07 | 2013-12-04 | H.隆德贝克有限公司 | 4-((1r,3s)-6-氯-3-苯基-茚满-1-基)-1,2,2-三甲基哌嗪和1-((1r,3s)-6-氯-3-苯基-茚满-1-基)-3,3-二甲基哌嗪的拆分方法 |
| JO3421B1 (ar) | 2011-06-20 | 2019-10-20 | H Lundbeck As | طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية |
| ES2719145T3 (es) | 2011-06-20 | 2019-07-08 | H Lundbeck As | 1-Piperazino-3-fenil-indanos deuterados para el tratamiento de la esquizofrenia |
| ES2595240T3 (es) | 2012-07-09 | 2016-12-28 | Lupin Limited | Derivados de tetrahidroquinazolinona como inhibidores de PARP |
| PL3462173T3 (pl) | 2012-08-21 | 2021-08-16 | Janssen Pharmaceutica Nv | Przeciwciała przeciwko rysperydonowi i ich zastosowanie |
| CN106928369B (zh) | 2012-08-21 | 2021-04-02 | 奥索临床诊断有限公司 | 喹硫平的抗体及其用途 |
| PT2887952T (pt) | 2012-08-21 | 2019-08-30 | Janssen Pharmaceutica Nv | Anticorpos para haptenos da olanzapina e suas utilizações |
| JP6270845B2 (ja) | 2012-08-21 | 2018-01-31 | ヤンセン ファーマシューティカ エヌ．ベー． | アリピプラゾールに対する抗体及びその使用 |
| PL2888284T3 (pl) | 2012-08-21 | 2023-02-27 | Janssen Pharmaceutica Nv | Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie |
| EP2888590B1 (en) | 2012-08-21 | 2020-07-08 | Janssen Pharmaceutica NV | Antibodies to olanzapine and use thereof |
| CN104736567B (zh) | 2012-08-21 | 2019-09-03 | 詹森药业有限公司 | 阿立哌唑半抗原的抗体及其用途 |
| EP2888277A4 (en) | 2012-08-21 | 2016-05-18 | Ortho Clinical Diagnostics Inc | ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF |
| ES2664952T3 (es) | 2012-08-21 | 2018-04-24 | Janssen Pharmaceutica Nv | Anticuerpos para haptenos de quetiapina y uso de los mismos |
| CN104736566A (zh) | 2012-08-21 | 2015-06-24 | 奥索临床诊断有限公司 | 帕潘立酮半抗原的抗体及其用途 |
| WO2014031584A1 (en) | 2012-08-21 | 2014-02-27 | Janssen Pharmaceutica Nv | Haptens of aripiprazole and their use in immunoassays |
| AR094054A1 (es) * | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
| EP3390455A1 (en) | 2015-12-17 | 2018-10-24 | Janssen Pharmaceutica NV | Antibodies to quetiapine and use thereof |
| EP3390449A1 (en) | 2015-12-17 | 2018-10-24 | Janssen Pharmaceutica N.V. | Antibodies to risperidone and use thereof |
| SI3661937T1 (sl) | 2017-08-01 | 2021-11-30 | Gilead Sciences, Inc. | Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb |
| EP3774742A1 (en) | 2018-04-06 | 2021-02-17 | H. Lundbeck A/S | Process for the preparation of 2,2-dimethylpiperazine |
| EP3873885A1 (en) | 2018-10-29 | 2021-09-08 | H. Lundbeck A/S | Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts |
| US11535600B2 (en) | 2018-12-03 | 2022-12-27 | H. Lundbeck A/S | Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine |
| US11358934B2 (en) * | 2020-03-23 | 2022-06-14 | Caamtech, Inc. | Crystalline forms of psilacetin |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4031216A (en) * | 1974-08-12 | 1977-06-21 | Knoll A.G. Chemische Fabriken | 3-(3,4-Dialkoxy-benzyl)-3-methyl-piperazines |
| IE50867B1 (en) * | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
| DE3139970A1 (de) * | 1981-10-08 | 1983-04-28 | Boehringer Mannheim Gmbh, 6800 Mannheim | Neue carbonsaeurederivate, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel |
| US5026853A (en) * | 1987-04-01 | 1991-06-25 | Janssen Pharmaceutica N.V. | 4-substituted-2(or 3)aminocarbonyl-1-piperazineacetamide |
| US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
| DE3837710A1 (de) * | 1988-11-07 | 1990-05-10 | Statomat Globe Maschf | Verfahren und vorrichtung zum ausrichten der abgemantelten enden von rundkabeln |
| ES2164054T3 (es) | 1991-11-05 | 2002-02-16 | Smithkline Beecham Corp | Antagonistas de receptores de endotelina. |
| CA2091204C (en) * | 1992-03-11 | 1997-04-08 | Ronald J. Mattson | Antiischemic-piperazinyl and piperidinyl-cyclohexanes |
| DK55192D0 (da) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
| JPH06184132A (ja) * | 1992-12-22 | 1994-07-05 | Kotobuki Seiyaku Kk | ベンゾフラン誘導体及びその製造方法並びに尿酸排泄剤 |
| ES2108484T3 (es) | 1993-11-30 | 1997-12-16 | Pfizer | Procedimiento para la preparacion de una tetralona asimetrica. |
| CA2132411A1 (en) * | 1994-09-19 | 1996-03-20 | Michael Trani | Enzymatic esterification of long-chain racemic acids and alcohols |
| US6410794B1 (en) * | 1994-12-16 | 2002-06-25 | Uop Llc | Process for preparation of pharmaceutically desired chiral tetralone from tetralones |
| US6455736B1 (en) * | 1994-12-16 | 2002-09-24 | Uop Llc | Process for preparation of pharmaceutically desired sertraline and sertraline analogs |
| US5807897A (en) * | 1996-03-01 | 1998-09-15 | Zeneca Limited | Aminotetralin derivative and compositions and method of use thereof |
| US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| ATE255555T1 (de) * | 1998-05-01 | 2003-12-15 | Pfizer Prod Inc | Verfahren zur herstellung von enantiomeren reinem oder optisch angereicherter sertraline-tetralon durch kontinuierliche chromatographie |
| CA2332459A1 (en) * | 1998-05-22 | 1999-12-02 | Scios Inc. | Heterocyclic compounds and methods to treat cardiac failure and other disorders |
| DE19824470A1 (de) | 1998-05-30 | 1999-12-02 | Boehringer Ingelheim Pharma | Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
| GB9818916D0 (en) | 1998-08-28 | 1998-10-21 | Smithkline Beecham Plc | Use |
| FR2786769B1 (fr) | 1998-12-04 | 2002-10-25 | Synthelabo | Derives de 2,5-diazabicyclo[2.2.1]heptane, leur preparation et leur application en therapeutique |
| JP2000351773A (ja) * | 1999-06-08 | 2000-12-19 | Yamanouchi Pharmaceut Co Ltd | フラン誘導体からなる医薬 |
| EP1059302A1 (en) * | 1999-06-08 | 2000-12-13 | Aventis Pharma Deutschland GmbH | Factor VIIa inhibitors |
| AR031520A1 (es) * | 1999-06-11 | 2003-09-24 | Vertex Pharma | Un compuesto inhibidor de aspartilo proteasa, una composicion que lo comprende y un metodo para tratar un paciente con dicha composicion |
| US6369226B1 (en) * | 1999-06-21 | 2002-04-09 | Agouron Pharmaceuticals, Inc. | Substituted benzamide inhibitors of rhinovirus 3C protease |
| IN187170B (hr) | 2000-01-04 | 2002-02-23 | Sun Pharmaceutical Ind Ltd | |
| BRPI0413555A (pt) | 2003-08-18 | 2006-10-17 | Lundbeck & Co As H | composto ou sal do mesmo, composição farmacêutica, uso de um composto ou sal, e, método para o tratamento de uma doença, para a fabricação de um composto e para a preparação de composto |
| TWI376373B (en) * | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
| JP2008530039A (ja) | 2005-02-16 | 2008-08-07 | ハー・ルンドベック・アクチエゼルスカベット | トランス−１−（（１ｒ，３ｓ）−６−クロロ−３−フェニルインダン−１−イル）−３，３−ジメチルピペラジンの酒石酸塩およびリンゴ酸塩 |
| TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
-
2004
- 2004-08-18 BR BRPI0413555-5A patent/BRPI0413555A/pt not_active IP Right Cessation
- 2004-08-18 AU AU2004265021A patent/AU2004265021B2/en not_active Ceased
- 2004-08-18 PL PL04762772T patent/PL1658277T3/pl unknown
- 2004-08-18 EP EP04739041A patent/EP1658276B1/en active Active
- 2004-08-18 NZ NZ544715A patent/NZ544715A/en not_active IP Right Cessation
- 2004-08-18 CA CA002536073A patent/CA2536073A1/en not_active Abandoned
- 2004-08-18 JP JP2006523528A patent/JP5043429B2/ja not_active Expired - Fee Related
- 2004-08-18 US US10/568,292 patent/US7772240B2/en not_active Expired - Fee Related
- 2004-08-18 BR BRPI0413595A patent/BRPI0413595B8/pt not_active IP Right Cessation
- 2004-08-18 EP EP04762772A patent/EP1658277B1/en active Active
- 2004-08-18 CA CA2536144A patent/CA2536144C/en not_active Expired - Fee Related
- 2004-08-18 AU AU2004265022A patent/AU2004265022A1/en not_active Abandoned
- 2004-08-18 MX MXPA06001838A patent/MXPA06001838A/es active IP Right Grant
- 2004-08-18 WO PCT/DK2004/000546 patent/WO2005016901A1/en active Application Filing
- 2004-08-18 MX MXPA06001938A patent/MXPA06001938A/es not_active Application Discontinuation
- 2004-08-18 JP JP2006523529A patent/JP5144930B2/ja not_active Expired - Fee Related
- 2004-08-18 US US10/568,572 patent/US7767683B2/en active Active
- 2004-08-18 WO PCT/DK2004/000545 patent/WO2005016900A1/en active Application Filing
- 2004-08-18 NZ NZ575575A patent/NZ575575A/en not_active IP Right Cessation
-
2006
- 2006-01-26 IS IS8265A patent/IS2848B/is unknown
- 2006-02-07 IL IL173589A patent/IL173589A0/en unknown
- 2006-02-16 IL IL173788A patent/IL173788A/en unknown
- 2006-03-10 NO NO20061153A patent/NO20061153L/no unknown
- 2006-03-10 NO NO20061151A patent/NO332048B1/no not_active IP Right Cessation
-
2010
- 2010-06-22 US US12/820,392 patent/US8227607B2/en active Active
- 2010-07-30 AU AU2010206058A patent/AU2010206058C1/en not_active Ceased
- 2010-11-04 US US12/939,904 patent/US8076342B2/en not_active Expired - Fee Related
-
2011
- 2011-07-13 JP JP2011154382A patent/JP5553802B2/ja not_active Expired - Fee Related
-
2012
- 2012-05-09 HR HRP20120389TT patent/HRP20120389T1/hr unknown
- 2012-05-24 CY CY20121100469T patent/CY1113039T1/el unknown
- 2012-12-10 HR HRP20121010TT patent/HRP20121010T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20121010T1 (hr) | Trans-1(6-klor-3-fenilindan-1-il)-3,3-dimetilpiperazin | |
| CN104603106B (zh) | 吲哚甲酰胺衍生物及其用途 | |
| JP6130071B2 (ja) | １，７−ナフチリジン誘導体 | |
| KR100393133B1 (ko) | 레보부피바카인및그의유사체의제조에사용하는라세미화및비대칭변환방법 | |
| JP2008509113A5 (hr) | ||
| HRP20110645T1 (hr) | Kristalična baza trans-1-((1r,3s)-6-kloro-3-fenilindan-1-il)-3,3-dimetilpiperazina | |
| WO2001076599B1 (en) | Process of making racemic bupivacaine's enantiomers, levobupivacaine's pharmaceutical compositions, levobupivacaine's pharmaceutical compositions formulated on its free base form or its pharmaceutical acceptable salts and use of levobupivacaine's pharmaceutical compositions formulated on its free base form | |
| DD273256A5 (de) | Verfahren zur herstellung von 3-amino-dihydro-[1]benzopyrane und benzothiopyrane | |
| CN105085482A (zh) | 取代的哌嗪化合物及其使用方法和用途 | |
| DD249480A5 (de) | 3-amino-dihydro-(1)-benzopyrane und benzothiopyrane | |
| DD147242A5 (de) | Verfahren zur herstellung von pyrido eckige klammer auf 2,1-b eckige klammer zu-chinazolinon-derivaten | |
| US4568695A (en) | 2-Amino-3-benzoyl-phenethylalcohols and intermediates therefor | |
| WO1999016431A1 (en) | Mixtures of enantiomers of aminocyclohexylamides to produce simultaneous analgesia with local anaesthesia or antiarrhythmia | |
| JP5095070B2 (ja) | Ｒ−（−）−１−［２−（７−クロロベンゾ［ｂ］チオフェン−３−イル−メトキシ）−２−（２，４−ジクロロフェニル）−エチル］−１Ｈ−イミダゾール | |
| CN111166745A (zh) | 含消旋氧吡格雷或其盐的组合物及应用 | |
| HU189745B (en) | Process for producing benzamido-derivatives | |
| CN111150731A (zh) | 含氧吡格雷光学异构体或其盐的组合物及应用 | |
| CN100422160C (zh) | 新的吗啉衍生物,其制备方法和含有它们的药物组合物 | |
| CN1128030A (zh) | 具有中枢神经系统活性的杂环胺 | |
| TW201249784A (en) | Compound, method for producing the same, and method for producing oseltamivir phosphate | |
| RU2001130147A (ru) | Пиридотиенодиазепины, способ их получения и содержащие их фармацевтические композиции | |
| JP2002527515A (ja) | 精神障害の処置のための３−テトラヒドロピリジン−４−イルインドール類 | |
| JPS60142972A (ja) | ４−（３−アルキニルオキシ−２−ヒドロキシ−プロピル）−ピペラジン−１−イル−ｎ−フエニル−アセタミド誘導体 | |
| CN105085436A (zh) | 磺酰胺类衍生物及其在药物上的应用 | |
| Cocolas et al. | Preparation and activity of β‐substituted acetylcholine iodides |